Nyrada Secures US Patent for Heart Protection Drug Candidate
MT Newswires Live
2 hours ago
Nyrada (ASX:NYR) secured a US composition-of-matter patent for Xolatryp, strengthening intellectual property protection for the drug candidate's chemical structure against unauthorized manufacture, use, sale, or import, according to an Australian bourse filing on Wednesday after market hours.
Xolatryp is being developed to protect the heart tissue from damage.
The patent has a 20-year term from its September 2024 filing date and is part of the company's broader global patent strategy, with applications planned in key markets, including Australia, Europe, and Japan, the filing added.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.